There are incredible breakthroughs being made right now by life sciences companies, which are exploring and developing new compounds with the potential to transform mental health treatment. But new drugs are just part of the solution.

Beckley Psytech’s CEO Cosmo Feilding Mellen comments on 5-MeO-DMT’s potential to rival psilocybin as a cost-effective psychedelic treatment for depression and addiction.

From magic mushrooms to ketamine, psychedelic drugs are having a serious heyday across the planet. Currently seeing considerable interest and acceptance by the public to treat emotional distress, the so-called third wave of psychedelics is cresting. And with that swelling attention is the creation of the essential machinery to support the new medical model — including consistent protocols and training preparation for clinicians.

Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has appointed ex-GW Pharmaceuticals CFO Adam George as a director with immediate effect.

Through most of the 20th century, the piobneering research in the use of psychedelics to treat mental health disorders has largely come out of the US.